Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 28:16:951202.
doi: 10.3389/fncel.2022.951202. eCollection 2022.

The role of Cdk5 in neurological disorders

Chuncao Ao  1 , Chenchen Li  1 , Jinlun Chen  1 , Jieqiong Tan  2   3   4 , Liuwang Zeng  1
Affiliations
Review

The role of Cdk5 in neurological disorders

Chuncao Ao et al. Front Cell Neurosci. .

Abstract

Neurological disorders are a group of disorders with motor, sensory or cognitive damage, caused by dysfunction of the central or peripheral nervous system. Cyclin-dependent kinases 5 (Cdk5) is of vital significance for the development of the nervous system, including the migration and differentiation of neurons, the formation of synapses, and axon regeneration. However, when the nervous system is subject to pathological stimulation, aberrant activation of Cdk5 will induce abnormal phosphorylation of a variety of substrates, resulting in a cascade signaling pathway, and thus lead to pathological changes. Cdk5 is intimately related to the pathological mechanism of a variety of neurological disorders, such as A-β protein formation in Alzheimer's disease, mitochondrial fragmentation in cerebral ischemia, and apoptosis of dopaminergic neurons in Parkinson's disease. It is worth noting that Cdk5 inhibitors have been reported to have neuroprotective effects by inhibiting related pathological processes. Therefore, in this review, we will briefly introduce the physiological and pathological mechanisms of Cdk5 in the nervous system, focusing on the recent advances of Cdk5 in neurological disorders and the prospect of targeted Cdk5 for the treatment of neurological disorders.

Keywords: CDK5 inhibitor; cyclin-dependent kinases 5 (Cdk5); nervous system; neurological disorders; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The role of Cdk5 in neurological disorders and the underlying molecular mechanisms.
Figure 2
Figure 2
The role of Cdk5 in neurodegenerative diseases. →: promote or aggravate; ⊣: inhibit or protect.
Figure 3
Figure 3
Molecular mechanisms of Cdk5 in some of the neurological diseases. →: promote or aggravate; ⊣: inhibit or protect.
Figure 4
Figure 4
Pathologicalmechanisms of Cdk5 in neurological disorders. When neurons are subjected to pathological stimuli, such as ischemia and toxic injury. Cdk5 is highly activated after binding to p25, phosphorylates many substrates, and also induces mitochondrial fragmentation, Golgi apparatus and endoplasmic reticulum dysfunction, and destruction of the cytoskeleton. Cdk5 inhibitors can attenuate or even reverse the above pathological processes.
See this image and copyright information in PMC

References

    1. Ai J., Wang H., Chu P., Shopit A., Niu M., Ahmad N., et al. . (2022). The neuroprotective effects of phosphocreatine on amyloid beta 25-35-induced differentiated neuronal cell death through inhibition of AKT/GSK-3β/Tau/APP/CDK5 pathways in vivo and vitro. Free Radic. Biol. Med. 179, 416–417. 10.1016/j.freeradbiomed.2021.12.306 - DOI - PubMed
    1. Alvarez-Periel E., Puigdellivol M., Brito V., Plattner F., Bibb J. A., Alberch J., et al. . (2018). Cdk5 contributes to Huntington’s disease learning and memory deficits via modulation of brain region-specific substrates. Mol. Neurobiol. 55, 6250–6268. 10.1007/s12035-017-0828-4 - DOI - PubMed
    1. Arif A. (2012). Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. Biochem. Pharmacol. 84, 985–993. 10.1016/j.bcp.2012.06.027 - DOI - PubMed
    1. Asada A., Saito T., Hisanaga S. (2012). Phosphorylation of p35 and p39 by Cdk5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner. J. Cell Sci. 125, 3421–3429. 10.1242/jcs.100503 - DOI - PubMed
    1. Banerjee J., Srivastava A., Sharma D., Dey S., Tripathi M., Sharma M. C., et al. . (2021). Differential regulation of excitatory synaptic transmission in the hippocampus and anterior temporal lobe by cyclin dependent kinase 5 (Cdk5) in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Neurosci. Lett. 761:136096. 10.1016/j.neulet.2021.136096 - DOI - PubMed

LinkOut - more resources